FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169403306> ?p ?o ?g. }

• W2169403306 endingPage "32" @default.
• W2169403306 startingPage "8" @default.
• W2169403306 abstract "Chemotherapy-induced neutropenia is a major risk factor for infection-related morbidity and mortality and also a significant dose-limiting toxicity in cancer treatment. Patients developing severe (grade 3/4) or febrile neutropenia (FN) during chemotherapy frequently receive dose reductions and/or delays to their chemotherapy. This may impact the success of treatment, particularly when treatment intent is either curative or to prolong survival. In Europe, prophylactic treatment with granulocyte-colony stimulating factors (G-CSFs), such as filgrastim (including approved biosimilars), lenograstim or pegfilgrastim is available to reduce the risk of chemotherapy-induced neutropenia. However, the use of G-CSF prophylactic treatment varies widely in clinical practice, both in the timing of therapy and in the patients to whom it is offered. The need for generally applicable, European-focused guidelines led to the formation of a European Guidelines Working Party by the European Organisation for Research and Treatment of Cancer (EORTC) and the publication in 2006 of guidelines for the use of G-CSF in adult cancer patients at risk of chemotherapy-induced FN. A new systematic literature review has been undertaken to ensure that recommendations are current and provide guidance on clinical practice in Europe. We recommend that patient-related adverse risk factors, such as elderly age (≥65 years) and neutrophil count be evaluated in the overall assessment of FN risk before administering each cycle of chemotherapy. It is important that after a previous episode of FN, patients receive prophylactic administration of G-CSF in subsequent cycles. We provide an expanded list of common chemotherapy regimens considered to have a high (≥20%) or intermediate (10-20%) risk of FN. Prophylactic G-CSF continues to be recommended in patients receiving a chemotherapy regimen with high risk of FN. When using a chemotherapy regimen associated with FN in 10-20% of patients, particular attention should be given to patient-related risk factors that may increase the overall risk of FN. In situations where dose-dense or dose-intense chemotherapy strategies have survival benefits, prophylactic G-CSF support is recommended. Similarly, if reductions in chemotherapy dose intensity or density are known to be associated with a poor prognosis, primary G-CSF prophylaxis may be used to maintain chemotherapy. Clinical evidence shows that filgrastim, lenograstim and pegfilgrastim have clinical efficacy and we recommend the use of any of these agents to prevent FN and FN-related complications where indicated. Filgrastim biosimilars are also approved for use in Europe. While other forms of G-CSF, including biosimilars, are administered by a course of daily injections, pegfilgrastim allows once-per-cycle administration. Choice of formulation remains a matter for individual clinical judgement. Evidence from multiple low level studies derived from audit data and clinical practice suggests that some patients receive suboptimal daily G-CSFs; the use of pegfilgrastim may avoid this problem." @default.
• W2169403306 created "2016-06-24" @default.
• W2169403306 creator A5007286394 @default.
• W2169403306 creator A5033285318 @default.
• W2169403306 creator A5046525319 @default.
• W2169403306 creator A5051999451 @default.
• W2169403306 creator A5053299342 @default.
• W2169403306 creator A5053872417 @default.
• W2169403306 creator A5056728544 @default.
• W2169403306 creator A5057952498 @default.
• W2169403306 creator A5060976792 @default.
• W2169403306 creator A5073060840 @default.
• W2169403306 creator A5075793922 @default.
• W2169403306 creator A5086157308 @default.
• W2169403306 date "2011-01-01" @default.
• W2169403306 modified "2023-10-14" @default.
• W2169403306 title "2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours" @default.
• W2169403306 cites W119861543 @default.
• W2169403306 cites W1546909751 @default.
• W2169403306 cites W1608439045 @default.
• W2169403306 cites W1737608283 @default.
• W2169403306 cites W1783154753 @default.
• W2169403306 cites W1783403542 @default.
• W2169403306 cites W1794992355 @default.
• W2169403306 cites W1808173951 @default.
• W2169403306 cites W1828514487 @default.
• W2169403306 cites W1831044128 @default.
• W2169403306 cites W1837121308 @default.
• W2169403306 cites W1848579801 @default.
• W2169403306 cites W1907938184 @default.
• W2169403306 cites W1923449517 @default.
• W2169403306 cites W1932169383 @default.
• W2169403306 cites W1932756735 @default.
• W2169403306 cites W1933587402 @default.
• W2169403306 cites W1935885922 @default.
• W2169403306 cites W1936664258 @default.
• W2169403306 cites W1946636618 @default.
• W2169403306 cites W1954043953 @default.
• W2169403306 cites W1954734300 @default.
• W2169403306 cites W1960713055 @default.
• W2169403306 cites W1964094292 @default.
• W2169403306 cites W1966872054 @default.
• W2169403306 cites W1966875672 @default.
• W2169403306 cites W1969787209 @default.
• W2169403306 cites W1972675392 @default.
• W2169403306 cites W1973535185 @default.
• W2169403306 cites W1974289641 @default.
• W2169403306 cites W1977123599 @default.
• W2169403306 cites W1978817748 @default.
• W2169403306 cites W1980041456 @default.
• W2169403306 cites W1980769405 @default.
• W2169403306 cites W1981913733 @default.
• W2169403306 cites W1984619574 @default.
• W2169403306 cites W1984650426 @default.
• W2169403306 cites W1986748792 @default.
• W2169403306 cites W1993608325 @default.
• W2169403306 cites W1993941594 @default.
• W2169403306 cites W1994926318 @default.
• W2169403306 cites W1996093663 @default.
• W2169403306 cites W1996429338 @default.
• W2169403306 cites W1997991692 @default.
• W2169403306 cites W1998018269 @default.
• W2169403306 cites W1998277689 @default.
• W2169403306 cites W1999086580 @default.
• W2169403306 cites W2000253139 @default.
• W2169403306 cites W2000900335 @default.
• W2169403306 cites W2001207261 @default.
• W2169403306 cites W2001850157 @default.
• W2169403306 cites W2002692636 @default.
• W2169403306 cites W2002814329 @default.
• W2169403306 cites W2004369760 @default.
• W2169403306 cites W2005747223 @default.
• W2169403306 cites W2005826254 @default.
• W2169403306 cites W2006252908 @default.
• W2169403306 cites W2007334755 @default.
• W2169403306 cites W2008252731 @default.
• W2169403306 cites W2009189135 @default.
• W2169403306 cites W2013042597 @default.
• W2169403306 cites W2023291563 @default.
• W2169403306 cites W2024933507 @default.
• W2169403306 cites W2025404731 @default.
• W2169403306 cites W2028716829 @default.
• W2169403306 cites W2029374110 @default.
• W2169403306 cites W2030596088 @default.
• W2169403306 cites W2033236068 @default.
• W2169403306 cites W2033261360 @default.
• W2169403306 cites W2034218339 @default.
• W2169403306 cites W2035811581 @default.
• W2169403306 cites W2035985743 @default.
• W2169403306 cites W2036067444 @default.
• W2169403306 cites W2036450045 @default.
• W2169403306 cites W2036913655 @default.
• W2169403306 cites W2037139573 @default.
• W2169403306 cites W2039332118 @default.
• W2169403306 cites W2039906080 @default.
• W2169403306 cites W2042418092 @default.
• W2169403306 cites W2043639465 @default.
• W2169403306 cites W2049014582 @default.

• next